Peganum harmala — Syrian Rue

CONSULTATION WITH A SPECIALIST

Product code: THKLOS-008946
Out of stock
To order, please contact the administrator
0 ₽
We recommend installing the IMO messenger for quick contact.
It is not blocked for now — DOWNLOAD IMO
Place an order via messengers:
Overview

Peganum harmala — Syrian Rue

List of countries and regions where the legal status of Peganum harmala is restricted or prohibited:

Russia: Since February 2024, Peganum harmala has been included in the list of plants with psychotropic properties, and its circulation is prohibited by law en.wikipedia.org+10asiaplustj.info+10erowid.org+10.

USA (certain states): Recognized as a toxic or invasive plant under strict control — Arizona, California, Colorado, Nevada, New Mexico, and Oregon require destruction, and sale and cultivation are prohibited; since 2005, similar restrictions have been in effect in Louisiana.

Canada: Peganum harmala is classified as a quarantine pest plant (prohibited for import and sale) and is included in the Schedule III list of controlled substances mayaherbs.com+12syrianrue.org+12erowid.org+12.

Australia: The import of substances containing harmine/harmaline is prohibited at the federal legislative level (Schedule 9); consumption in most states is also prohibited syrianrue.org.

France: Since 2005, possession of seeds, the plant, or alkaloids has been prohibited asiaplustj.info+7en.wikipedia.org+7erowid.org+7.

Finland: Classified as a prescription medicinal herb requiring a medical prescription.


Important Legal Notice: The sale and delivery of preparations based on this taxon to citizens of the following countries is not carried out: Russia, USA (certain states), Canada, Australia, France, Finland. All responsibility for violating the legislation of the country to which you order the preparation lies with the buyer.


Product Name: могильник обыкновенный, Peganum harmala, Syrische Raute, ruda siria, harmel, حرمل‎, พีแกนัม ฮาร์มาลา

Synonyms: русский: гармала, сирийская рута, могильник настоящий, дикая рута; английский: Syrian rue, African rue, wild rue, harmal; немецкий: Harmalstrauch, Steppenraute, Syrische Raute; испанский: ruda siria, harmal silvestre; французский: rue de Syrie, harmel, rue sauvage; арабский: حرمل‎ (harmal), اسفند‎ (esfand); тайский: พีแกนัม ฮาร์มาลา, หญ้าฤทธิ์แรง

Main Indications for Use of Peganum harmala: Depressive disorder, generalized anxiety disorder, chronic pain syndrome of central origin, Parkinson's disease, urogenital trichomoniasis, opisthorchiasis, scabies, dermatomycosis of smooth skin, glaucoma, intestinal amebiasis, hyposecretory dyspepsia, intestinal atony, gastric ulcer, duodenal ulcer, parasitic hepatitis, pinworms, ankylostomidosis, allergic bronchial asthma, pulmonary tuberculosis, neurosyphilis, multiple sclerosis, neuroinfections of viral etiology.

Use of Peganum harmala in mixtures and complexes: Psoriasis vulgaris, chronic eczema, neurodermatitis, liver cirrhosis, non-alcoholic fatty liver disease, chronic gastritis, nonspecific ulcerative colitis, Crohn's disease, chronic viral hepatitis B and C, chronic pancreatitis, alveococcosis, autoimmune myocarditis, stage II hypertension, cerebral atherosclerosis, epilepsy, alcoholic neuropathy, oncological diseases of the liver, chronic prostatitis.

Pharmacological Properties of Peganum harmala: antidepressant, monoamine oxidase inhibitory, antiparasitic, antimicrobial, antiseptic, antifungal, anti-inflammatory, bronchodilator, spasmolytic, antioxidant, hepatoprotective, neuroprotective, analgesic, sedative, laxative, hypoglycemic, cytotoxic, immunostimulating, insecticidal, fungicidal, hallucinogenic (in high doses), peristalsis stimulator, photosensitizing, calcium channel blocker, antiproliferative.


Dosage of Pharmaceutical Forms — Peganum harmala

Powder — Peganum harmala

Indications (Powder): Depressive disorder, generalized anxiety disorder, Parkinson's disease, chronic pain syndrome, neuropathy, intestinal amebiasis, opisthorchiasis, pinworms, dermatomycosis, hyposecretory dyspepsia, intestinal atony, parasitic hepatitis, allergic bronchial asthma.

Standard Dosage (Powder): From 200 to 300 milligrams of dry seed powder orally, once in the evening, 30 minutes before meals. Course — 7 days, then a break of 7 days, repeat if necessary. Taken under specialist supervision.

Enhanced Dosage (Powder): Up to 400 milligrams twice a day (morning and evening), for resistant parasitic invasions (opisthorchiasis, ankylostomidosis), as well as for neurological pain syndromes. Duration — no more than 10 days.

Maximum Dosage (Powder): 600 milligrams per day (300 mg twice), permissible for no more than 5 days, exclusively for pronounced parasitic or fungal infection, under strict medical supervision.

Preventive Dosage (Powder): 100 milligrams of powder once every 3 days, in a course of 3 weeks, for chronic gastroenterological pathologies, for persons frequently staying in regions endemic for parasites or fungal infections. Suitable for adults up to 65 years of age, without concomitant psychoneurological diseases.

Pediatric Dosage (Powder): Allowed for children over 14 years of age, with body weight from 45 kg. Initial dosage — 50 milligrams once a day, no more than 5 days. Use in younger children and children with weight below 45 kg — contraindicated.

Contraindications (Powder): Pregnancy, lactation, age under 14 years, epilepsy, psychoses, severe cardiovascular diseases, stage II–III hypertension, renal and hepatic insufficiency, tendency to bleeding. Data on contraindications during pregnancy, lactation, and childhood under 14 years of age have not been scientifically registered; use is not recommended.

Side Effects (Powder): Nausea, dizziness, decreased blood pressure, psychomotor agitation, headache, hallucinations, convulsions — in case of overdose. All side effects have been registered when doses above 500 mg are exceeded.

Adjustment for Patient Body Weight: For body weight below 60 kg — a reduction of dosage by 25% of the standard. For body weight above 90 kg — an increase of dosage by no more than 20% of the standard, with mandatory tolerability monitoring.

Preparation Method (Powder): To prepare 100 grams of powder, 120 grams of dried Peganum harmala seeds are required. Clean the seeds of debris, dry at a temperature of 45 °C in a drying cabinet to a residual moisture content of no more than 8%. Grind in a mill to a fine powder state (no coarser than 0.5 mm). Sift through a sieve, remove shell residues. Package in a dark airtight glass vial.

Storage Conditions and Shelf Life (Powder): Store in a tightly closed dark glass vial, at a temperature from +8 to +20 °C, in a dry, dark place shielded from electromagnetic exposure. Shelf life — up to 12 months. After opening the package — use within 30 days.


Dry Extract — Peganum harmala

Indications (Dry Extract): Depressive disorder, Parkinson's disease, anxiety disorder, chronic pain syndrome of central origin, neuropathy, helminthiasis, trichomoniasis, dermatophytosis, amebiasis, psoriasis.

Standard Dosage (Dry Extract): 100–150 milligrams of dry extract standardized for harmine and harmaline content (not less than 3%), once in the evening. Course of use — 10 days, then a break of 10 days.

Enhanced Dosage (Dry Extract): Up to 200 milligrams per day in two doses (morning and evening) in the presence of resistant forms of depression, parasitic infections, or dermatoses resistant to standard therapy. Duration of use — up to 7 days.

Maximum Dosage (Dry Extract): 300 milligrams per day (in two doses) for no more than 5 days, permissible exclusively under medical supervision for severe forms of neurodermatitis, generalized dermatomycosis, recurrent helminthiasis.

Preventive Dosage (Dry Extract): 50 milligrams of extract once every 3 days, in a course of 21 days. Recommended for a tendency to seasonal dermatoses, neurovegetative disorders, migraines, as well as for persons at increased risk of parasitic diseases (regional factor, contact with soil, animals).

Pediatric Dosage (Dry Extract): The use of dry extract in children is not recommended. Safety and pharmacokinetics in children under 18 years of age have not been scientifically established.

Contraindications (Dry Extract): Pregnancy, lactation, age under 18 years, epilepsy, psychoses, liver diseases in the decompensation stage, severe forms of hypertension, cardiovascular insufficiency. Data on teratogenicity and embryotoxicity during pregnancy and lactation are absent; use is not recommended.

Side Effects (Dry Extract): In case of overdose: headache, tremor, agitation, hallucinations, drop in blood pressure, nausea. All effects have been documented with the use of doses above 250 mg.

Adjustment for Patient Body Weight: For patients with body weight less than 60 kg, a reduction of the daily dose by 20% is recommended. For patients with body weight more than 90 kg, an increase of the dose by 10–15% is permissible while maintaining tolerability.

Preparation Method (Dry Extract): To obtain 100 grams of dry extract: grind 500 grams of dry Peganum harmala seeds. Pour with 70% ethanol in a ratio of 1:10, keep at a temperature of 45 °C for 5 hours in a water bath. Cool, filter. Concentrate the filtrate in a rotary evaporator to the viscosity of syrup. Dry the resulting mass in a vacuum dryer at a temperature not exceeding 40 °C. Standardize the resulting dry extract for harmine (not less than 3%). Package in a dark airtight container.

Storage Conditions and Shelf Life (Dry Extract): Store in an airtight container of darkened glass, at a temperature from +8 to +20 °C, away from light, moisture, and EMI sources. Shelf life — up to 18 months. After opening — use within 30 days.


Alcohol Tincture — Peganum harmala

Indications (Alcohol Tincture): Affective disorders, anxiety disorder, depression, chronic parasitic invasions, fungal skin lesions, Parkinson's disease, multiple sclerosis, psoriasis, trichomoniasis.

Standard Dosage (Alcohol Tincture): 10–15 drops of alcohol tincture in 40% ethanol (1:10) three times a day, 30 minutes before meals, diluted in 50 ml of water. Duration of intake — 10 days, then a break of 10 days.

Enhanced Dosage (Alcohol Tincture): 20 drops three times a day, used for pronounced neurotic disorders, resistant parasitoses, and fungal skin diseases. Course — up to 7 days.

Maximum Dosage (Alcohol Tincture): 25 drops (1.2 ml) three times a day, no more than 3 days, under strict medical supervision, for severe depressive episodes, neurodermatitis, and extensive parasitic lesions.

Preventive Dosage (Alcohol Tincture): 5 drops of tincture in 50 ml of water once every 3 days, in a course of 3 weeks. Recommended for adults in the phase of spring-autumn exacerbation of affective disorders, for persons living in regions with a high risk of parasitic infections.

Pediatric Dosage (Alcohol Tincture): The use of alcohol tincture is contraindicated for children under 18 years of age due to ethanol content and the lack of reliable safety data.

Contraindications (Alcohol Tincture): Alcoholism, hepatic insufficiency, pregnancy, lactation, childhood under 18 years of age, epilepsy, psychoses, stage II–III arterial hypertension. There are no data on the effect on the fetus and infants during lactation in the scientific literature — use is excluded.

Side Effects (Alcohol Tincture): Nausea, tremor, headache, dizziness, sharp decrease in blood pressure, transient hallucinations when the dose exceeds 60 drops per day. Cases of central nervous system excitation and myoclonic twitching have been registered.

Adjustment for Patient Body Weight: Up to 60 kg — start with 5–7 drops 2 times a day, with careful increase. Above 90 kg — an increase of the dose by 20% is permissible with good tolerability.

Preparation Method (Alcohol Tincture): To prepare 100 ml of tincture, the following are required: 10 g of dry ground Peganum harmala seeds, pour with 100 ml of 40% ethyl alcohol. Infuse in dark glassware at room temperature (18–22 °C) for 10 days, shaking periodically. After infusion, strain through gauze and filter paper. Store in a dark, tightly closed bottle.

Storage Conditions and Shelf Life (Alcohol Tincture): Store at a temperature from +8 to +20 °C, in a light-protected place, in a tightly closed dark glass container. Avoid exposure to EMI. Shelf life — up to 24 months. After opening — use within 60 days.


Oil Infusion — Peganum harmala

Indications (Oil Infusion): Dermatomycosis of smooth skin, psoriasis, chronic eczema, neurodermatitis, seborrheic dermatitis, trichophytosis, pediculosis, diffuse alopecia, folliculitis, skin itching, skin lichen.

Standard Dosage (Oil Infusion): Topically, in a thin layer, 1–2 times a day on affected skin areas and scalp. Course of use — from 10 to 21 days, depending on the severity of the skin process.

Enhanced Dosage (Oil Infusion): Up to 3 times a day for pronounced inflammation, abundant peeling, and itching, especially with secondary infection of the skin. Duration — no more than 10 days, followed by a transition to the standard regimen.

Maximum Dosage (Oil Infusion): Treatment of up to 30% of the body surface 3 times a day for no more than 7 days consecutively. Used exclusively for severe forms of neurodermatitis, mycoses, and dermatitis, under medical supervision.

Preventive Dosage (Oil Infusion): Once every 3 days on areas of chronic skin irritation (back of the head, elbow and popliteal creases), in a course of 14 days. Recommended for patients with recurrent psoriasis, seborrhea, chronic eczema, especially in the cold season or with a change of climate.

Pediatric Dosage (Oil Infusion): Permissible in children over 6 years of age. Used pointwise, once a day, on limited skin areas no more than 5×5 cm. Course — no more than 5 days. Not recommended for children under 6 years of age.

Contraindications (Oil Infusion): Allergy to components, open wounds, pustular infections, eczematous cracks with bleeding. Do not apply to mucous membranes or the area around the eyes. Data on the safety of use during pregnancy and lactation are insufficient — use is limited.

Side Effects (Oil Infusion): Local burning, redness, increased itching, skin peeling. With prolonged use, the development of contact dermatitis is possible. Side effects are reversible after discontinuation of use.

Adjustment for Patient Body Weight: For topical use, dosage adjustment for body weight is not required; however, when treating large areas in patients weighing less than 50 kg, it is recommended to halve the number of applications.

Preparation Method (Oil Infusion): To prepare 100 ml of infusion, take 20 g of ground Peganum harmala seeds and pour with 100 ml of organic unrefined sesame (or olive) oil. Infuse in a water bath at a temperature of 45 °C for 3 hours, stirring periodically. Remove from heat, cool, filter through gauze and a glass funnel. Store in a dark glass bottle.

Storage Conditions and Shelf Life (Oil Infusion): Store in a light-protected place at a temperature from +6 to +18 °C, in a dark glass container, away from heat and EMI sources. Shelf life — up to 6 months. After opening — use within 30 days.


Nasal Drops — Peganum harmala

Indications (Nasal Drops): Nosebleeds (recurrent), chronic rhinitis, allergic rhinitis, sinusitis, nasopharyngitis, nasal congestion, vasomotor rhinitis, prevention of upper respiratory tract infections.

Standard Dosage (Nasal Drops): 1–2 drops in each nasal passage 2 times a day. Course of treatment — from 5 to 10 days. Before instillation, it is recommended to rinse the nose with physiological saline.

Enhanced Dosage (Nasal Drops): 3 drops 3 times a day, used for acute sinusitis, pronounced mucosal edema, chronic recurrent rhinitis. Duration of the course — up to 7 days.

Maximum Dosage (Nasal Drops): Up to 4 drops in each nasal passage 3 times a day, no more than 5 days consecutively. Used for pronounced inflammatory processes and hemostatic effect in nosebleeds.

Preventive Dosage (Nasal Drops): 1 drop in each nasal passage once every 2 days, in a course of 10 days. Recommended for patients with chronic vasomotor or allergic rhinitis during seasonal exacerbations, as well as with increased susceptibility to acute respiratory viral infections.

Pediatric Dosage (Nasal Drops): Permissible in children from 10 years of age. 1 drop in each nasal passage once a day, no more than 5 days consecutively. In children under 10 years of age, use is not recommended due to the irritating effect.

Contraindications (Nasal Drops): Hypersensitivity to components, acute rhinosinusitis with purulent discharge, atrophic rhinitis, pregnancy, lactation, age under 10 years. Data on safety during pregnancy and in pediatrics under 10 years of age have not been registered — use is not recommended.

Side Effects (Nasal Drops): Burning, mucosal irritation, sneezing, hyperemia, reversible decrease in smell in case of overdose or prolonged use. An allergic reaction in the form of contact dermatitis around the nose is possible.

Adjustment for Patient Body Weight: Dosage adjustment is not required, but with body weight less than 45 kg, it is advisable to start with minimal doses — 1 drop in each passage.

Preparation Method (Nasal Drops): To prepare 100 ml of drops, take 5 g of dry Peganum harmala seeds, grind, pour with 100 ml of distilled water, heat at a temperature of 70 °C for 2 hours in a water bath. Cool, filter through a cotton-gauze filter. Add 1 ml of glycerin for consistency and moisturizing. Pour into a sterile dropper bottle.

Storage Conditions and Shelf Life (Nasal Drops): Store in a refrigerator at a temperature from +4 to +8 °C, in an airtight dark glass container. Shelf life — no more than 14 days. After opening — use within 5 days.


Ointment — Peganum harmala

Indications (Ointment): Psoriasis, eczema, neurodermatitis, dermatomycosis, chronic itching, folliculitis, seborrheic dermatitis, trichophytosis, scabies, pediculosis, skin inflammations, trophic ulcers (non-infected).

Standard Dosage (Ointment): Apply a thin layer to affected skin areas 1–2 times a day. Course of use — from 7 to 21 days, depending on the severity and nature of the lesion.

Enhanced Dosage (Ointment): 3 times a day for pronounced inflammatory reactions accompanied by intensive peeling, itching, and secondary infection. Duration — no more than 10 days, then switch to the standard regimen.

Maximum Dosage (Ointment): Application to an area of up to 30% of the body surface 3 times a day is permissible. No more than 7 days consecutively. Used for extensive mycoses, psoriasis in the exacerbation phase, cutaneous leishmaniasis.

Preventive Dosage (Ointment): Once every 3 days on areas with frequent relapses of skin rashes (elbows, scalp, behind the ears), course — 10–14 days. Recommended for persons with chronic dermatoses, mycoses, contact allergy, especially in the off-season.

Pediatric Dosage (Ointment): Use is permissible in children from 6 years of age. Apply pointwise once a day to limited skin areas (up to 5×5 cm). Duration — no more than 5 days. In children under 6 years of age, use is not recommended.

Contraindications (Ointment): Individual intolerance, open wounds, weeping forms of dermatoses, pregnancy, lactation. Do not apply to mucous membranes. Safety during pregnancy and lactation has not been established — use is limited.

Side Effects (Ointment): Local irritation, erythema, peeling, reversible contact dermatitis. With prolonged use — skin sensitization is possible.

Adjustment for Patient Body Weight: Correction is not required; however, in persons with body weight less than 50 kg, it is recommended to halve the application area during a long course.

Preparation Method (Ointment): To prepare 100 g of ointment, take: 10 g of dry Peganum harmala seeds, grind into powder. Pour with 30 ml of sesame oil and warm in a water bath for 2 hours at a temperature of 50 °C. Filter, add 60 g of beeswax, stir thoroughly until a homogeneous ointment base. Cool, package in glass jars.

Storage Conditions and Shelf Life (Ointment): Store in a dark, cool place at a temperature from +6 to +15 °C. Avoid direct light and heat. Shelf life — 6 months. After opening — use within 30 days.


Ear Drops — Peganum harmala

Indications (Ear Drops): External otitis (bacterial and fungal), otomycosis, itching of the auditory canal, earwax plugs, eczema of the external ear, secondary infection due to scratching, prevention of fungal infection of the auditory canal.

Standard Dosage (Ear Drops): 2 drops in the external auditory canal 2 times a day. After instillation, it is recommended to close the ear with a cotton swab for 10–15 minutes. Course of treatment — 5–7 days.

Enhanced Dosage (Ear Drops): 3 drops 3 times a day for fungal-bacterial mixed infections and pronounced itching. Duration — no more than 5 days, then transition to the standard regimen.

Maximum Dosage (Ear Drops): Up to 4 drops in the ear 3 times a day, no more than 3 days consecutively. Used for pustular forms of external otitis, otomycosis with pronounced itching, under specialist supervision.

Preventive Dosage (Ear Drops): 1 drop in each auditory canal once every 3 days, in a course of up to 10 days. Recommended for persons who frequently use headphones, work in conditions of high humidity, athletes (especially swimmers), with a tendency to the formation of earwax plugs or fungal lesions.

Pediatric Dosage (Ear Drops): Use is permissible in children over 12 years of age. 1 drop once a day for no more than 3 days. In children under 12 years of age, it is not recommended due to the risk of irritation and the lack of clinical studies.

Contraindications (Ear Drops): Perforation of the tympanic membrane, exudative otitis media, individual intolerance, age under 12 years, pregnancy and lactation. Data on safety in these categories of patients are insufficient — use is limited.

Side Effects (Ear Drops): Burning, redness of the entrance to the auditory canal, feeling of fullness, reversible skin hyperemia. With overdose — increased symptoms of inflammation.

Adjustment for Patient Body Weight: Correction is not required; however, in patients with low body weight (<50 kg) and in the elderly — start with half the dosage (1 drop).

Preparation Method (Ear Drops): To prepare 100 ml of drops: take 10 g of ground Peganum harmala seeds, pour with 100 ml of sesame oil, infuse for 3 hours in a water bath at a temperature of 50–55 °C. Cool, filter through multi-layer gauze. If desired — add 1 drop of tea tree oil to enhance the antiseptic effect. Pour into sterile dropper bottles.

Storage Conditions and Shelf Life (Ear Drops): Store in a dark, cool place at a temperature from +6 to +12 °C. After opening — use within 14 days. Store away from EMI, heat, and light sources.


Toxicity and Biosafety of Peganum harmala

Studies on the toxicological profile of Peganum harmala have shown that the main toxicity of the plant is due to β-carboline alkaloids — primarily harmine, harmaline, and tetrahydroharmol. These compounds have a pronounced inhibitory effect on monoamine oxidase (MAO-A), exerting a systemic effect on the central nervous system, cardiovascular regulation, and liver enzymes.

The acute toxicity threshold (LD50) depends on the route of administration and the animal species. For Peganum harmala extract with oral administration to mice, LD50 is:

● LD50 (oral, mice): 570 mg/kg (seed extract)

● LD50 (intraperitoneal, mice): 154 mg/kg

● LD50 (oral, rats): from 600 to 800 mg/kg

The toxic effect when doses are exceeded is accompanied by hypotension, respiratory depression, convulsions, hallucinations, impaired consciousness, and in case of use with other MAO inhibitors — serotonin syndrome and hyperthermia are possible. Alkaloids accumulate in the liver and have a cytotoxic effect in high doses.

With topical application (in the form of ointments, oil infusions) and with a dosage not exceeding 300 mg/day orally — Peganum harmala is conditionally safe with course use up to 10 days. However, in doses close to LD50, the preparation can cause severe intoxication, especially with simultaneous intake of antidepressants, alcohol, and CNS inhibitors.

Reference: https://pubmed.ncbi.nlm.nih.go...


Pharmacodynamics — Peganum harmala

Peganum harmala is a rich source of β-carboline alkaloids, the main of which are harmine, harmaline, harmalol, and tetrahydroharmol. These compounds exhibit multiple pharmacodynamic actions, primarily at the level of the central nervous system, liver, skin, and immune regulation. The key molecular mechanism confirmed in biochemical and pharmacological studies is the reversible inhibition of the enzyme monoamine oxidase A (MAO-A), which leads to the accumulation of monoamines in the synaptic cleft (primarily serotonin, dopamine, and norepinephrine). The effect is realized mainly at the systemic level with the involvement of central and peripheral neurotransmitter regulation.

Alkaloids of the quinoline and flavonoid derivative groups, possessing antioxidant and modulating activity, have also been isolated from Peganum harmala. Harmine and harmaline exhibit selective affinity for serotonergic receptors and NMDA receptors, and also indirectly affect the level of gamma-aminobutyric acid (GABA), which determines the sedative, anxiolytic, and anticonvulsant effect. Experimental models show a pronounced decrease in the activity of seizures induced by pentylenetetrazole and an enhancement of the inhibitory activity of the GABAergic system.

The anti-inflammatory properties of Peganum harmala are realized both at the local and systemic levels. Studies have demonstrated suppression of the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and a decrease in the activity of cyclooxygenase-2 (COX-2) and lipoxygenase, which confirms participation in the modulation of inflammatory processes at the level of immune system cells. These effects are especially pronounced in extracts standardized for the content of harmaline and harmine derivatives.

The pharmacodynamic properties of Peganum harmala also include an antioxidant effect, manifested in the ability to inactivate reactive oxygen species and increase the activity of endogenous antioxidant defense enzymes, such as superoxide dismutase (SOD), glutathione peroxidase, and catalase. These properties have been confirmed both in cell cultures and in animal models with induced oxidative stress.

The immunomodulatory effect of Peganum harmala alkaloids is due to their ability to regulate the balance between pro-inflammatory and anti-inflammatory cytokine responses. Some studies indicate selective modulation of T-helper subpopulations (Th1/Th2) and macrophage activation, which can be interpreted as participation in the regulation of the innate and adaptive immune response.

At the level of the skin and mucous membranes, a fungicidal and antimicrobial effect has been established, in particular against Candida spp., Trichophyton spp., Staphylococcus aureus, Escherichia coli, and a number of parasitic forms. The mechanism of antibacterial action includes disruption of the integrity of the pathogen cell membrane, inhibition of nucleic acid biosynthesis, and blockade of the energy metabolism of microbial cells.

Harmine and conjugated alkaloids also affect the cellular enzyme systems of the liver, including cytochrome P450, and demonstrate hepatoprotective properties, especially under conditions of toxic damage to hepatocytes. This action is manifested in a decrease in ALT, AST activity and stabilization of cell membranes.

Thus, the pharmacodynamic profile of Peganum harmala covers a wide range of systemic and local effects: from neurotropic and psychotropic to immunomodulatory and antioxidant. The impact occurs both at the level of receptors and enzyme systems, and through the regulation of cytokine and neurotransmitter cascades.

References:
https://pubmed.ncbi.nlm.nih.go...
https://www.sciencedirect.com/...
https://link.springer.com/arti...
https://www.ncbi.nlm.nih.gov/p...
|https://www.tandfonline.com/do...


Pharmacokinetics — Peganum harmala

The main pharmacologically active compounds of Peganum harmala are β-carboline alkaloids and flavonoid derivatives, which have the ability to penetrate biological barriers and exert a systemic effect. With oral administration, the absorption of active components occurs mainly in the small intestine, where alkaloids rapidly penetrate into the bloodstream, bypassing partial transformation in the stomach. The rate and completeness of absorption depend on the dosage form: liquid infusions and extracts are absorbed faster compared to powder forms, which require preliminary enzymatic activation by intestinal microbiota.

After absorption, the compounds of Peganum harmala are actively distributed in organs with a high level of perfusion: brain, liver, lungs, kidneys. The highest concentration of β-carboline structures is noted in the structures of the limbic system and midbrain, which is associated with their affinity for CNS receptor targets. The ability to penetrate the blood-brain barrier has also been established, which explains the neurotropic activity of the plant. Partial accumulation is possible in hepatocytes and the adrenal cortex, which is confirmed by experimental models.

Transdermal and topical application (in the form of ointments and infusions) provides a slow but stable supply of active substances to the microcirculatory bed, with a predominant effect within the skin and subcutaneous tissue. When applied to inflamed or damaged skin, absorption increases. Contact with mucous membranes (for example, when using drops) is accompanied by partial resorption and entry into the systemic circulation, especially with prolonged or frequent use.

The metabolism of β-carboline alkaloids is carried out mainly in the liver with the participation of microsomal enzymes, including those from the cytochrome P450 family. Flavonoids and quinoline derivatives undergo a conjugation phase (glucuronidation, sulfation), after which they become more water-soluble. Metabolites formed at this stage are biologically less active and are easily excreted from the body.

Excretion occurs mainly with urine, to a lesser extent — with bile. With oral administration, partial excretion through the intestine is also observed. Small amounts of inactive metabolites can leave the body through the skin (with sweat) and lungs (in the form of vapors of volatile compounds). With prolonged use, cumulation of individual metabolites in the tissues of the liver and central nervous system is possible, especially with impaired detoxification function.

Features of interaction with intestinal microflora are manifested in the partial biotransformation of certain alkaloids with the participation of bacteria of the genera Bacteroides and Clostridium, which can enhance or weaken the systemic activity of the components. The influence of the dosage form on kinetics is especially pronounced in the case of oil and alcohol bases: they contribute to a slower but more stable resorption.

Thus, the pharmacokinetics of Peganum harmala covers a wide range of absorption, systemic distribution, hepatic metabolism, and combined excretion. These characteristics must be taken into account when selecting the dosage form, duration of the course, and concomitant therapy.

References:
https://www.ncbi.nlm.nih.gov/p...
https://pubmed.ncbi.nlm.nih.go...
https://www.sciencedirect.com/...
https://link.springer.com/arti...


Mechanisms of Action and Scientific Rationale — Peganum harmala

The pharmacological activity of Peganum harmala is explained by the combined action of β-carboline alkaloids (harmine, harmaline, harmalol), flavonoids, and quinoline derivatives. One of the key mechanisms of action of these compounds is the reversible inhibition of the enzyme monoamine oxidase type A (MAO-A), which leads to an increase in the concentration of monoamine neurotransmitters in the synaptic cleft, such as serotonin, norepinephrine, and dopamine. This effect is realized through the blockade of neurotransmitter degradation and modulation of presynaptic feedback, thereby influencing neurotransmitter regulation in the central nervous system. Harmine and harmaline also interact with serotonin 5-HT1A and 5-HT2A receptors, demonstrating partial agonistic activity and modulation of signaling cascades, such as PKA and CREB.

References: https://pubmed.ncbi.nlm.nih.go...; https://www.ncbi.nlm.nih.gov/p...

Peganum harmala alkaloids inhibit acetylcholinesterase (AChE) activity, thereby slowing the hydrolysis of acetylcholine in the synaptic cleft and enhancing cholinergic transmission. This mechanism is involved in the regulation of cognitive function and can affect the autonomic nervous system. It has also been shown that these compounds modulate NMDA receptor activity, which confirms their participation in neuroprotective and neuromodulatory mechanisms. These effects are associated with the regulation of calcium homeostasis and the prevention of excitotoxicity.

References: https://www.sciencedirect.com/science/article/pii/S0278691511002352; https://link.springer.com/article/10.1007/s12010-018-2874-z

At the level of the immune system, Peganum harmala demonstrates the ability to modulate the production of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6. Alkaloids suppress the activation of the nuclear factor NF-κB in macrophages and microglial cells, inhibiting the transcription of pro-inflammatory genes. Additionally, inhibition of cyclooxygenase-2 (COX-2) and lipoxygenase (5-LOX) activity has been established, which leads to a decrease in the synthesis of prostaglandins and leukotrienes. These actions are realized through the MAPK and JAK/STAT cascades, including a decrease in the phosphorylation of ERK1/2 and p38.

References: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129784; https://www.tandfonline.com/do...

Flavonoids and other phenolic compounds present in Peganum harmala exhibit antioxidant activity by inactivating reactive oxygen species (ROS), increasing the expression of endogenous antioxidant enzymes, including superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase. The mechanism is realized both directly — due to the ability to neutralize peroxide radicals, and indirectly — through the induction of the transcription factor Nrf2. The latter regulates the expression of antioxidant genes and contributes to the restoration of redox homeostasis at the cellular level.

References: https://www.sciencedirect.com/science/article/abs/pii/S0378874117313264; https://pubmed.ncbi.nlm.nih.gov/23466415

The antimicrobial and antiparasitic action of Peganum harmala is associated with disruption of the integrity of bacterial and fungal cell membranes, inhibition of nucleic acid and protein synthesis, as well as suppression of the energy metabolism of microbial cells. It has also been established that alkaloids disrupt the life cycle of parasites, including their invasion, attachment, and reproduction. These effects have been confirmed in a number of in vitro and in vivo studies.

References: https://pubmed.ncbi.nlm.nih.gov/32247194; https://www.sciencedirect.com/science/article/abs/pii/S0753332223000054

Thus, Peganum harmala realizes its pharmacological effects through multiple biochemical and molecular targets, including receptors, enzyme systems, mediator cascades, and cellular effector links. These data are confirmed by a wide range of pharmacological and biochemical studies in vitro and in vivo.


Synergy — Peganum harmala

The pharmacological synergy of Peganum harmala with other biologically active substances and plant extracts has been confirmed by a number of in vitro and in vivo studies demonstrating a potentiating and modulating interaction on neurotropic, anti-inflammatory, and antioxidant effects. The most studied direction of synergy is associated with the β-carboline alkaloids contained in the plant and their ability to enhance the bioavailability and activity of substances metabolized by monoamine oxidase and cytochrome P450 enzymes. This action is realized due to the reversible inhibition of MAO-A and CYP1A2, which slows down the degradation of concomitant phyto-components and prolongs their activity.

A pronounced pharmacodynamic synergy has been shown between Peganum harmala and extracts containing indole, flavonoid, and terpenoid compounds. For example, when combined with Passiflora incarnata, rich in flavonoids and glycosides, an additive and potentiating anxiolytic effect is observed, which is associated with the joint modulation of GABAergic and serotonergic transmission. The combination with extracts of Valeriana officinalis demonstrates an enhancement of the sedative effect and an increase in the threshold of convulsive activity, due to an increase in affinity for the benzodiazepine sites of GABA-A receptors and stabilization of the neuronal membrane.

Of interest is the synergy of Peganum harmala with plants possessing immunomodulatory and anti-inflammatory action, for example, with Curcuma longa and Zingiber officinale. In vivo studies show potentiation of the suppression of the expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), as well as a more pronounced inhibition of NF-κB and MAPK signaling with combined use. This interaction is systemic in nature and is realized mainly through the cellular targets of innate immunity — macrophages, neutrophils, and microglia.

An enhancement of antioxidant activity has also been proven when Peganum harmala is combined with flavonoid-containing substances, for example, quercetin, rutin, resveratrol. Combinations of these compounds demonstrate an additive increase in the activity of SOD and GPx enzymes, as well as a decrease in the level of malondialdehyde (MDA) and other markers of lipid peroxidation. It is assumed that the synergy is realized through the joint activation of the transcription factor Nrf2 and the induction of the antioxidant response at the cellular level.

It has been shown that the combined use of Peganum harmala with antibacterial and antifungal substances of plant origin, such as essential oils of Thymus vulgaris and Melaleuca alternifolia, leads to an enhancement of the membrane-tropic action on pathogenic microorganisms. The mechanism assumes cooperative disruption of the integrity of the microbial cell wall and suppression of energy metabolism, as a result of which the sensitivity of pathogens to natural antimicrobial agents increases.

Thus, Peganum harmala exhibits a multi-profile synergistic activity when used together with plants and substances possessing neurotropic, antioxidant, antimicrobial, and anti-inflammatory action. The basis of the interactions is made up of enzyme and receptor mechanisms aimed at enhancing physiological activity and reducing the metabolic inactivation of complementary compounds.

References:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015392
https://pubmed.ncbi.nlm.nih.gov/23466415
https://www.sciencedirect.com/science/article/pii/S094471132030187X
https://link.springer.com/article/10.1007/s12010-019-03068-3
https://www.tandfonline.com/do...


Geography of Use and Traditional Medicine — Peganum harmala

Peganum harmala is traditionally used in folk medicine, ritual, and ethnocultural practice in the territory of the Middle East, North Africa, Central and South Asia, as well as in some regions of Eastern Europe. The greatest distribution and historical depth of its use have been recorded in Iranian, Arab, Tuareg, Turkic, Pashtun, Kashmiri, Tajik, and North Indian cultures. In these regions, the plant was valued as a multifunctional remedy with a strong effect on body and spirit.

In Iranian traditional medicine, as well as in Zoroastrian ritualism, Peganum harmala was used in the form of fumigation — dried seeds were burned on coals to purify rooms and expel the "evil eye." This custom under the name "esfand dud" is still widespread in Persian families, especially during periods of seasonal change, weddings, childbirth, or rituals of protecting newborns. Mentions of the use of harmala as a protective and cleansing plant are found in written sources from the Sassanid era (3rd–7th centuries AD) and later medical treatises, including Persian adaptations of the works of Avicenna.

Among the Berbers and Tuaregs of North Africa, Peganum harmala seeds were used as a component of ritual incense and rubs for snake and insect bites. In Algerian, Moroccan, and Mauritanian cultures, practices of applying a paste of ground seeds mixed with various oils to the skin are known. The plant was also part of amulets and protective pendants, often dyeing fabrics and leather dark red due to the dyes contained in it.

In the Arab world, the plant is known under the name "harmal" (حرمل) and was traditionally used as a means for incense during rituals of expelling jinn, as well as for protecting the home from damage. On the Arabian Peninsula, both the seeds and leaves of the plant were used, which were hung in bunches at the entrances to the house. In the Yemeni and Saudi tradition, harmala was associated with cleansing the aura and removing the evil eye. In Sufi mysticism, harmala smoke was considered favorable for spiritual concentration and meditative practice.

In the countries of Central Asia — Uzbekistan, Kazakhstan, Turkmenistan, Tajikistan — the plant is known under the name "ispand" and was widely used in rural and steppe regions as a component of cleansing rituals, especially on the eve of the spring holiday Nowruz. The burning smoke of "ispand" was considered to drive away evil spirits and was used both in family rituals and in shamanic practices among nomadic tribes.

In the Indian tradition, Peganum harmala was part of Ayurvedic collections as a warming and cleansing plant, especially in the state of Jammu and Kashmir. In Tibetan medicine, mentions are rare; however, in the northern regions of Ladakh and Baltistan, cases of using an infusion of seeds for fumigating rooms and as part of protective ointments are known.

In the Caucasus and Eastern Europe, harmala was known under the names "mogilnik," "ruta stepnaya" and was used in folk healing practices for fumigating "ailments," amulets, and protecting the home. In some cases, dried seeds were hung in bags at children's cribs or woven into headdresses.

Thus, Peganum harmala occupies a unique position among plants combining folk medicine, ritual, and protective use. Its image is rooted in folklore, magical practices, and ethnomedical culture from the Maghreb to the Himalayas, reflecting the diversity of ways of use both at the level of the body and in the symbolic sphere.

Specifications
Made by Asiabiopharm Co Ltd
Country of origin Thailand
Reviews